Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. DVA
D

DaVita Inc. (DVA)

NYQ – Real Time Price. Currency in USD

154.43

-2.33 (-1.49%)

At close: Mar 27, 2026, 4:00 PM EDT

154.40

-0.03 (-0.02%)

After-hours: Mar 27, 2026, 8:00 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Should Value Investors Buy DaVita (DVA) Stock?
27.03.2026

Should Value Investors Buy DaVita (DVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
18.03.2026

DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know
17.03.2026

DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $149.98, denoting a +1.19% move from the preceding trading day.

4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts
17.03.2026

4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts

An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
17.03.2026

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, today announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals, Ltd.

4 Stocks Trading Near 52-Week Highs With Room to Rise Further
16.03.2026

4 Stocks Trading Near 52-Week Highs With Room to Rise Further

Investors target stocks that have been on a bullish run. Stocks like STRA, SHIP, DVA and FE are seeing price strength, and the momentum is likely to continue.

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
16.03.2026

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Videos

03.02.2026
Positive
TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings